Description
Ovagen (Glu-Asp-Leu) is a synthetic tripeptide of the Khavinson bioregulator class with tissue-specific action on the female reproductive system, particularly ovarian function. The substance was developed at the St. Petersburg Institute for investigating age-related ovarian function changes.
Per study reports Ovagen modulates gene expression in granulosa and theca cells of the ovary via the Khavinson epigenetic mechanism. Preclinical studies describe effects on steroidogenesis, follicle maturation, and age-related ovarian reserve markers.
In Russian research literature Ovagen is described in perimenopausal and postmenopausal aging models, with subjective improvements in energy and wellbeing. International replication is very limited.
Typical application is subcutaneous in 10-20 day courses two to three times per year.
You can order Ovagen as lyophilized peptide in 10-pack at 20mg per vial.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Ovagen is classified as very mild in the available literature and is among the most well tolerated compounds of the Khavinson bioregulator class. In the available preclinical and limited human studies, no relevant toxic effects have been documented.
Observed in research and reports:
- Injection site: mild redness or transient irritation with subcutaneous use is the most common observation. The tripeptide itself is considered low-reactivity.
- Very thin human data: the data base consists almost entirely of small, Russian-language studies from the Khavinson environment. International replication is very limited, and robust long-term safety data on reproductive use do not exist.
- Course-based pattern: the use described occurs in short 10-20 day courses. No data exist on the safety profile of continuous administration.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Peptide bioregulation of aging: results and prospects - Biogerontology 2009, Anisimov and Khavinson: Overview of the Khavinson bioregulator class, with documented lifespan extension and reduced tumor incidence in aging models.
- Peptide Regulation of Aging: 35-Year Research Experience - Bulletin of Experimental Biology and Medicine 2009, Khavinson and Anisimov: review of the tissue-specific tripeptides and their action on reproductive and endocrine gene expression.
- Peptide bioregulators: A new class of geroprotectors. Message 1: Results of experimental studies - Advances in Gerontology 2013, Khavinson, Kuznik and Ryzhak: experimental data on Khavinson bioregulators across multiple organ systems including the reproductive tract.
- Peptides, genome, aging - Advances in Gerontology 2014, Khavinson: mechanism overview of tripeptide-DNA interaction and tissue-specific gene expression modulation.
